Hair Loss Treatments: 2026 AI Market Discovery Index

Answer Capsule

In the Hair Loss Treatments category for June 2026, AI platforms are concentrating recommendation power around a small set of brands. Nutrafol leads with the highest AI Authority Value at $3.9M, driven by broad recommendation coverage across all six tracked platforms. Rogaine follows as a strong second, particularly dominant in Top 1 recommendations. Keeps captures significant value through visibility assist. Bosley, HairClub, and Folexin appear in AI responses but rarely receive ranked recommendations, exposing a structural gap between brand recognition and shortlist eligibility.

Executive Summary

AI platforms are reshaping how consumers discover hair loss treatments, and the June 2026 data shows a clear concentration of recommendation power around three brands. Nutrafol leads with a monthly AI Authority Value of $3.9M, capturing 7.3% of the total $53.2M monthly AI opportunity. Rogaine follows at $2.5M, distinguished by a Top 1 recommendation rate of 14.2% and an average recommended rank of 1.58. Keeps holds third at $3.2M, though a meaningful share of its value derives from visibility assist rather than direct recommendations.

The most commercially significant pattern is the divergence between presence and recommendation power. Bosley appears in 7.7% of all AI observations but receives valid recommendations in only 0.8% of cases. HairClub shows a comparable pattern. These brands are being retrieved by AI systems and then passed over, a position that is commercially worse than simple invisibility because it consumes brand equity without producing outcomes.

Hims and Happy Head occupy a credible middle tier. Hims achieves a 9.7% Top 10 recommendation rate and Happy Head reaches 10.6%, with the highest net sentiment score in the category at 0.80. Neither brand, however, approaches the recommendation breadth of the top three.

The commercial implication is direct. AI platforms are functioning as shortlist builders in this category. Brands that consistently reach Top 3 recommendations capture the majority of the $53.2M modeled monthly opportunity. Brands that are mentioned without being ranked are effectively excluded from the buying moment, regardless of their clinical reputation or advertising presence.

The AI Discovery Shift in Hair Loss Treatments

Hair loss treatment selection has historically depended on dermatologist referrals, direct-to-consumer advertising, and clinical reputation built over years. AI platforms are introducing a new discovery layer that operates independently of these channels. When a consumer asks an AI system which hair loss treatment to consider, the system retrieves, evaluates, and ranks options based on available public evidence, without any input from the brand's marketing team or clinical staff.

The critical commercial distinction is between being mentioned and being recommended. Bosley is mentioned. Rogaine is recommended. Those are not equivalent outcomes. A mention signals that the AI system has retrieved the brand. A recommendation signals that the system trusts the brand enough to advance it as a choice. For a category where consumer trust and clinical credibility are decisive, that distinction is the difference between appearing on a shortlist and being excluded from one.

Ranked recommendations matter because they compress buyer consideration. Across the three public clusters, brands appearing in Top 3 positions capture the majority of observed recommendation value. Brands outside the Top 10 in high-intent queries are, for practical purposes, not in the conversation.

Public source architecture is the mechanism behind these rankings. AI systems retrieve evidence from clinical references, dermatologist review content, comparison articles, and structured brand content before forming a recommendation. Brands with stronger public evidence layers are more likely to be advanced. Brands with weak or thin citation architecture are retrieved and then deprioritized, regardless of brand size.

Directional Category Leaders

1. Nutrafol

Nutrafol leads the category with a monthly AI Authority Value of $3.9M, capturing 7.3% of the total AI opportunity. It achieves the highest Top 10 recommendation rate at 22.7% and the broadest valid recommendation coverage at 24.9%. Presence across all observations reaches 47.4%, the highest in the category. Platform performance is consistent rather than concentrated: Copilot contributes 30.9% recommendation coverage, Google AI Overviews 28.0%, with solid performance across the remaining four platforms. The average recommended rank of 2.24 is strong, though marginally behind Rogaine on that single metric.

The public interpretation: Nutrafol has built the most consistent AI recommendation architecture in the category, appearing and being advanced across all major platforms rather than dominating on one.

2. Rogaine

Rogaine holds second position with a monthly AI Authority Value of $2.5M and a 4.7% captured share. Its defining strength is Top 1 recommendation dominance. A Top 1 rate of 14.2% and an average recommended rank of 1.58 are the best in the category on both measures. On ChatGPT specifically, Rogaine captures 19.8% of the platform opportunity with a Top 1 rate of 25.1%. On Perplexity, it achieves a 30.9% Top 3 rate. Presence sits at 31.9%, the second highest in the category. Rogaine's authority appears rooted in decades of clinical citation and regulatory approval history, providing the evidence layer AI systems favor in evaluation contexts.

The public interpretation: Rogaine is the most frequently recommended first-choice option in the category, particularly strong when AI systems are directly comparing treatment options.

3. Keeps

Keeps ranks third with a monthly AI Authority Value of $3.2M. A notable share of that figure derives from visibility assist rather than direct ranked recommendations. Its Top 10 rate of 7.2% and Top 3 rate of 6.6% are lower than both Nutrafol and Rogaine. The average rank of 2.13 is competitive when Keeps does receive a recommendation, but recommendation frequency is the limiting factor. Google AI Overviews is the strongest platform, where Keeps captures 13.6% of the platform opportunity. Net sentiment of 0.60 is slightly below the category leaders.

The public interpretation: Keeps has strong assisted visibility but lower direct recommendation frequency, suggesting it is commonly retrieved alongside other brands without consistently being advanced ahead of them.

4. Hims

Hims registers a monthly AI Authority Value of $1.0M with a 1.9% captured share. A Top 10 rate of 9.7% and Top 3 rate of 9.4% are credible, and an average rank of 1.67 indicates strong positioning when Hims does receive a recommendation. Google AI Mode is the strongest platform, contributing 5.1% of platform opportunity. Presence at 15.9% is solid but significantly behind the top three. Hims appears to benefit from strong telehealth comparison content but lacks the clinical citation depth that supports broader recommendation coverage.

The public interpretation: Hims performs well in specific contexts but is consistently outranked by Nutrafol and Rogaine across high-intent discovery moments.

5. Happy Head

Happy Head achieves a monthly AI Authority Value of $478.8K with a 0.9% captured share. Its Top 10 rate of 10.6% and Top 3 rate of 9.2% are competitive for a brand of its scale. The average rank of 2.14 is strong. The standout figure is net sentiment of 0.80, the highest in the category, indicating that when AI systems discuss Happy Head, the framing is consistently positive. Google AI Mode is the primary platform contributor at 2.5% of opportunity. Recommendation breadth remains the limiting factor.

The public interpretation: Happy Head generates the most favorable AI sentiment in the category but lacks the recommendation frequency to challenge the top three at scale.

6. Bosley

Bosley presents the category's clearest visibility-to-recommendation gap. It appears in 7.7% of observations but receives valid recommendations in only 0.8% of cases. The Top 10 rate is 0.6%, and the monthly AI Authority Value is $99.8K, representing 0.2% of the total category opportunity. Bosley is not being ignored by AI systems; it is being retrieved and then passed over. This is the most commercially dangerous position in AI-driven discovery.

The public interpretation: Bosley's brand recognition does not translate into recommendation power, leaving it visible but commercially marginal in AI search contexts.

7. Ro (Roman), HairClub, Folexin, Propecia (Merck)

These four brands collectively capture less than 0.2% of the total AI opportunity. Ro (Roman) achieves a 1.1% Top 10 rate. HairClub appears in 3.0% of observations but generates virtually no valid recommendations. Folexin and Propecia (Merck) show minimal presence and negligible recommendation coverage across all platforms.

The public interpretation: Each of these brands is effectively absent from AI-generated shortlists in the current measurement period.

The Buying Moments That Now Decide the Category

Best Telehealth and Online Prescription Services (Consideration)

This cluster covers 416 observations with a modeled opportunity of $20.6M. It represents consumers in the initial awareness and early consideration phase, asking broad questions about available treatment options. Nutrafol leads with a 21.4% Top 10 rate and $1.3M in captured value. Rogaine follows at 18.0% and $945.7K. Keeps captures $1.4M in total value, driven largely by visibility assist in this wide-funnel context. This cluster sets the initial shortlist that buyers carry into more specific evaluation queries.

Telehealth Platform Comparisons (Evaluation)

This cluster spans 310 observations with a $15.5M opportunity. It represents consumers actively comparing platforms before deciding. Rogaine dominates with a 24.8% Top 10 rate and a 24.5% Top 3 rate, the strongest recommendation performance observed in any single cluster. Nutrafol follows at 19.4% Top 10. The concentration of value around two brands in this cluster signals that AI systems have formed clear comparative preferences in evaluation contexts. Brands absent here are losing the decision-stage conversation entirely.

Telehealth and Online Prescription Pricing (Decision)

This cluster has 376 observations and a $17.0M opportunity, making it the highest-intent and highest-value cluster in the public dataset. Consumers here are ready to act. Nutrafol leads with a 26.9% Top 10 rate and $1.6M in captured value. Rogaine follows at 13.3% Top 10. Happy Head shows its strongest cluster performance here, reaching a 12.8% Top 10 rate and an average rank of 1.48 in this context. Brands that do not appear in pricing-intent queries are absent precisely when purchase probability is highest.

Why Recommendation Power Is Concentrating

Recommendation power is concentrating because AI systems require evidence to justify a recommendation, not simply to retrieve a brand. Nutrafol and Rogaine benefit from extensive clinical study references, independent dermatologist review content, structured brand pages, and comparison articles that give AI platforms multiple retrieval paths and citation sources. This depth of public evidence allows AI systems to retrieve, compare, and confidently advance these brands when forming a response.

Keeps and Hims benefit from strong telehealth comparison content and direct-to-consumer brand architecture. Their presence in comparison-oriented sources explains their performance in evaluation clusters. The relative weakness in clinical citation depth may explain why they are more likely to be retrieved alongside other brands than advanced ahead of them.

Bosley and HairClub, despite decades of market presence, appear to have thin public citation architecture relative to their brand recognition. AI systems can identify them as category participants but cannot find sufficient structured evidence to support a recommendation. This is not a product quality issue. It is a source visibility issue.

The concentration dynamic is self-reinforcing over time. Brands that consistently appear in Top 3 recommendations generate additional consumer engagement, which produces more review content, more comparison mentions, and more citation sources, which strengthens their AI evidence layer further. Brands outside the Top 10 face a widening gap with each reporting cycle.

The Category's Most Visible Warning Sign

Bosley is the clearest warning sign in this dataset. Bosley is a nationally recognized hair restoration brand with decades of clinical presence and consumer awareness. In the June 2026 data, it appears in 85 of 1,102 observations. It receives 9 valid recommendations. Its Top 10 rate is 0.6%. Its monthly AI Authority Value is $99.8K, representing 0.2% of the category opportunity.

The problem is not invisibility. AI systems know Bosley exists. The problem is that knowing a brand exists and recommending it are different outcomes, and AI systems are making that distinction at scale, consistently, across six platforms. Bosley is occupying the most commercially inefficient position available: present enough to be compared, not trusted enough to be chosen. Every observation in which Bosley is retrieved and passed over is a moment where a competitor captures the commercial value instead.

What This Means for the Category

Shortlist compression is the defining market dynamic. Three brands capture the majority of recommendation value across all three public high-intent clusters. The gap between the top three and the rest is not marginal; it is structural. Brands outside the top five are being excluded from AI-generated shortlists in the moments where consumer intent is highest and purchase probability is greatest.

Competitor displacement is accelerating as a consequence. Hims and Happy Head have built credible positions, but both are consistently outperformed by Nutrafol and Rogaine in recommendation coverage. For Bosley, HairClub, and the lower tier, displacement is already complete in the AI channel. They are present in the category conversation without participating in the recommendation economy.

Trust-source dependency is becoming a durable structural advantage. Brands with strong clinical citation architecture, dermatologist review content, independent comparison coverage, and structured entity presence are being systematically preferred by AI systems. This advantage compounds over time and is not easily closed by advertising spend or brand awareness investment alone.

AI discovery is becoming a standard component of the consumer buying journey in hair loss treatments. The $53.2M monthly modeled opportunity represents a growing share of the category's acquisition value. Brands that do not build the entity, content, source, and citation architecture that AI systems use to evaluate and recommend options will find their shortlist eligibility eroding with each reporting cycle, regardless of their standing in traditional channels.

What This Public Benchmark Does Not Include

This public version does not include:

- Full cluster dataset covering all 10 tracked high-intent clusters

- Prompt-level response tables showing brand performance for specific queries

- Citation-source failure maps identifying which sources are missing or underperforming

- Platform-by-platform recovery priorities for each brand

- Entity and schema diagnostics

- Source-layer gap analysis

- Company-specific content recommendations

- Exact competitor threat profiles by cluster and platform

- Full paid opportunity model

This page shows the market shape. The paid report shows the repair map.

Methodology and Disclaimers

This analysis covers 1,102 observations collected in June 2026 across six AI platforms: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, and Perplexity. The company universe includes 10 brands in the Hair Loss Treatments category. Three public high-intent clusters are reported here. The full report covers 10 clusters.

AI Authority Value is a modeled metric combining recommendation value and visibility assist value. It is directional and does not represent a full market census. Presence, recommendation coverage, rank, net sentiment, and modeled value are separate signals and should not be conflated or treated as interchangeable. This analysis is not a regulatory, quality, compliance, or product audit. It measures AI system recommendation behavior, not treatment efficacy, clinical outcomes, or product safety.

Request a Company-Specific Report

For a company-specific Authority Index report, the deeper analysis would show which prompts each company wins or loses, which AI platforms are under-recognizing the brand, which source layers are shaping recommendations, and what changes may improve AI shortlist eligibility.